Home
Live Updates
Biogen Ends Development of Alzheimers Drug Aduhelm : comparemela.com
Biogen Ends Development of Alzheimer's Drug Aduhelm
Biogen will record a one-time charge of about $60 million related to close-out costs of the program.
Related Keywords
Adam Glanzman Bloomberg ,
Emily Dattilo ,
Drug Administration ,
Article Normal ,
Biotechnology Services ,
Pharmaceuticals ,
Banking ,
Commercial Banking ,
Healthcare Life Sciences ,
Banking Credit ,
Specialized Drugs Medications ,
Financial Services ,
Neurodegenerative Disease Drugs ,
Political General News ,
Dementia ,
Health ,
Medical Conditions ,
Mental Disorders ,
Synd ,
Biotech And Pharma ,
Markets ,
North America ,
Healthcare ,
Rapid Response ,
Eisai ,
4523 To ,
Jp 4523 ,
Biogen ,
Biib ,
Political ,
General News ,
Life Sciences ,
Credit ,
Specialized Drugs ,
Medications ,
comparemela.com © 2020. All Rights Reserved.